Several companies on the Wall Street have seen some Seeking Alpha analyst activity, including both upgrades and downgrades in ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has ...